Gentherm Lifts 2026 Outlook, Launches $400M Buyback, and Delivers Record Q2 Revenue
THRM sits 31% above its 52-week low of $27.
Summary
Record Q2 revenue of $416M, raised full-year 2026 guidance, and a new $400M stock buyback authorization highlight Gentherm's latest update. The company also acquired a medical device firm, expanding its healthcare portfolio as it advances toward closing the Modine Performance Technologies merger.
Key Events · Earnings and Guidance · THRM
-
Record Q2 Revenue and Profit Growth
Product revenues climbed 11.0% year over year to $416.2M, driven by a 14.1% increase in Automotive Climate and Comfort Solutions. Net income jumped to $4.4M from $0.5M, and adjusted diluted EPS advanced to $0.75 versus $0.54.
-
Full-Year 2026 Guidance Raised
The revenue outlook now stands at $1.55B–$1.65B, up from $1.5B–$1.6B. Adjusted EBITDA guidance was lifted to $185M–$200M (previously $175M–$195M), and adjusted free cash flow is expected to reach $85M–$100M, compared with the prior range of $80M–$100M.
-
New $400M Stock Repurchase Authorization
The board terminated the existing $150M program, which had $110.1M remaining, and authorized a new $400M buyback over three years, expiring July 27, 2029. Repurchases may be funded through cash, borrowings, or future offerings.
-
Medical Acquisition Broadens Healthcare Portfolio
The acquisition of Innovative Medical Equipment, LLC adds the ThermaZone thermal therapy device and creates cross-selling opportunities across healthcare channels, complementing the recent FDA clearance for the ThermAffyx Patient Safety System.
Analysis · THRM · Manufacturing
A record quarterly revenue of $416 million, a full-year guidance raise across all key metrics, and a new $400 million stock repurchase program — replacing a smaller prior authorization — underscore a quarter of strong execution and a decisive pivot toward shareholder returns. The acquisition of Innovative Medical Equipment further deepens the healthcare footprint ahead of the planned Modine Performance Technologies merger. While the buyback represents an authorization rather than executed purchases and the merger remains pending, the combination of robust operational momentum, upgraded guidance, and a sizable capital-return commitment signals clear management confidence.
At the time of this filing, THRM was trading at $35.50 on NASDAQ in the Manufacturing sector, with a market capitalization of approximately $1.1B. The 52-week trading range was $27.00 to $39.48. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.